Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
SW-682 in Advanced Solid Tumors
NCT06251310 · View on ClinicalTrials.gov ↗
Study Summary
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
Conditions Studied
Interventions
- DRUG SW-682
- DRUG Combination Therapy
Study Locations (8)
California
- UC San Diego Moores Cancer Center — La Jolla
- USC/Norris Comprehensive Cancer Center — Los Angeles
- SpringWorks Clinical Trial Site — Los Angeles
Texas
- Mary Crowley Cancer Research — Dallas
- The University of Texas MD Anderson Cancer Center — Houston
Arizona
- SpringWorks Clinical Trial Site — Scottsdale
Ohio
- University Hospitals Cleveland Medical Center — Cleveland
Oregon
- Knight Cancer Institute Clinical Trials — Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2024-07-30 |
| Est. Completion | 2030-06 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06251310
The ClinicalTrials.gov registry entry for NCT06251310 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SpringWorks Therapeutics, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions — of which SW-682 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06251310 reports 8 study locations spanning 5 distinct geographic areas — top geographies include California, Texas, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06251310 about?
NCT06251310 is a clinical study titled "SW-682 in Advanced Solid Tumors". This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after ap...
What is the current status of trial NCT06251310?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2024-07-30. Estimated completion is 2030-06.
What conditions does trial NCT06251310 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Mesothelioma, Malignant. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06251310?
The interventions under investigation include: SW-682 (DRUG), Combination Therapy (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06251310?
This trial is sponsored by SpringWorks Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06251310 being conducted?
This trial has 8 study locations across Arizona, California, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.